Drug search by name

Ruzurgi and Liver disease

Result of checking the interaction of drug Ruzurgi and disease Liver disease for safety when used together.

Check result:

Ruzurgi <> Liver disease

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Amifampridine is extensively metabolized by N-acetyltransferase 2 (NAT2) and hepatic impairment may cause an increase in exposure. The effects of amifampridine have not been studied in patients with hepatic impairment. It is recommended to start treatment with amifampridine in patients with any degree of hepatic impairment at the lowest recommended starting dosage (15 mg/day) and monitor for adverse reactions. Consider dosage modification or discontinuation in patients with hepatic impairment as clinically appropriate.

Ruzurgi

Generic Name: amifampridine

Brand Name: Ruzurgi, Firdapse

Synonyms: n.a.

What is Ruzurgi?